Selecta Biosciences appoints Blaine Davis as CFO, replacing Kevin Tan

Cartesian Therapeutics, Inc.

Blaine Davis named CFO effective Nov 28, 2022; Kevin Tan stepped down amicably.
Davis receives $440,000 base salary, 40% target bonus, and option for 1,250,000 shares vesting over 4 years.
Tan receives full 2022 bonus and equity vesting through Jan 4, 2023 per separation agreement.
Davis previously CFO at Protara Therapeutics; over 25 years biopharma finance experience.
Company highlights upcoming Phase 3 gout readout, Phase 1/2 MMA trial, and IL-2 candidate selection.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Blaine Davis

Chief Financial Officer

RNAC · Cartesian Therapeutics, Inc.

Effective: 2022-11-28
Filed: November 28, 2022, 6:59 PM ET

On November 22, 2022, the Board of Directors (the “Board”) of Selecta Biosciences, Inc. (the “Company”) appointed Blaine Davis as the Company’s Chief Financial Officer, effective upon the commencement of Mr. Davis’s full-time employment with the Company on November 28, 2022 (the “Effective Date”).

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Blaine Davis was appointed as Chief Financial Officer at Cartesian Therapeutics, Inc..

Action: appointed
Role: Chief Financial Officer

Exact text from the filing

On November 22, 2022, the Board of Directors (the “Board”) of Selecta Biosciences, Inc. (the “Company”) appointed Blaine Davis as the Company’s Chief Financial Officer, effective upon the commencement of Mr. Davis’s full-time employment with the Company on November 28, 2022 (the “Effective Date”).

View on SEC.gov

Cartesian Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-22-292939

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.